Agonists for the peroxisome proliferator-activated receptor-α and the retinoid X receptor inhibit inflammatory responses of microglia

Journal of Neuroscience Research

Volumn 81, Issue 3, 2005, Pages 403-411

  Xu, Jihong ^a   Storer, Paul D ^a   Chavis, Janet A ^a   Racke, Michael K ^b   Drew, Paul D ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Chemokine; Cytokine; Microglia; PPAR

Indexed keywords

ALITRETINOIN; CIPROFIBRATE; CYTOKINE; FENOFIBRATE; GEMFIBROZIL; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; RETINOID X RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; LIPID METABOLISM; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; CHEMOKINES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; INTERFERON TYPE II; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICROGLIA; NITRIC OXIDE; PEROXISOME PROLIFERATORS; PPAR ALPHA; RETINOID X RECEPTORS; TETRAZOLIUM SALTS; THIAZOLES; TRETINOIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 25444528680     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20518     Document Type: Article

References (52)

1. Ando DG, Clayton J, Kono D, Urban JL, Sercarz EE. 1989. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 124:132-143.
2. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. 2001. TNF-alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4:1116-1122.
3. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. 1993. Surface expression of alpha-4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177:57-68.
4. Benveniste EN. 1997. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med 75:165-173.
5. Cannella B, Raine CS. 1995. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37:424-435.
6. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. 2000. The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses. J Immunol 164:1364-1371.
7. Cunard R, DiCampli D, Archer DC, Stevenson JL, Ricote M, Glass CK, Kelly CJ. 2002a. WY14, 643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J Immunol 169:6806-6812.
8. Cunard R, Ricote M, DiCampli D, Archer DC, Kahn DA, Glass CK, Kelly CJ. 2002b. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol 168:2795-2802.
9. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui , Haegeman AG, Staels B. 1999. Peroxisome proliferator-activated receptor a negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 274:32048-32054.
10. Delerive P, Gervois P, Fruchart JC, Staels B, 2000. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators. J Biol Chem 275:36703-36707.
11. Desvergne B, Wahli W. 1999. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-688.
12. Diab A, Deng C, Smith JD, Hussain RZ, Phanavanh B, Lovett-Racke AE, Drew PD, Racke MK. 2002. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta (12, 14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 168:2508-2515.
13. Diab A, Hussain RZ, Lovett-Racke AE, Chavis JA, Drew PD, Racke MK. 2004. Ligands for peroxisome proliferators-activated receptor-γ and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J Neuroimmunol 148: 116-126.
14. 12,14 prostaglandin J2 represses nitric oxide, TNF-α, and IL-12 production by microglial cells. J Neuroimmunol 115:28-35.
15. Feinstein D, Galea E, Gavriluk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Henkeka MT. 2002. Peroxisome-proliferator activated receptor-γ agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 51: 694-702.
16. Fenyk-Melody JE, Garrison AE, Brunnert SR, Weidner JR, Shen F, Shelton BA, Mudgett JS. 1998. Experimental autoimmune encephalomyelitis is exacerbated in mice lacking the NOS2 gene. J Immunol 160:2940-2946.
17. Gran B, Zhang G-X, Rostami A. 2004. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit Rev Immunol 24:111-128.
18. Jiang C, Ting AT, Seed B. 1998. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86.
19. Kawahito Y, Kondo M, Tsubouchi Y, Hashiramoto A, Bishop-Bailey D, Inoue K, Kohno M, Yamada R, Hla T, Sano H. 2000. 15-deoxy-Delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 106:189-197.
20. Kennedy KJ, Karpus WJ. 1999. Role of chemokines in the regulation of Th1/Th2 and autoimmune encephalomyelitis. J Clin Immunol 19:273-279.
21. Kennedy KJ, Strieter RM, Kunkel SL, Lukacs NW, Karpus WJ. 1998. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1. J Neuroimmunol 92:98-108.
22. Kielian T, Drew PD. 2003. Effects of peroxisome proliferators-activated receptor-gamma agonists on central nervous system inflammation. J Neurosci Res 71:315-325.
23. Lee C-H, Olson P, Evans RM. 2003. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144:2201-2207.
24. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. 2000. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523-531.
25. Lovett-Racke AE, Racke MK. 2002. Retinoic acid promotes the development of Th2-like human myelin basic protein-reactive T cells. Cell Immunol 215:54-60.
26. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD, Racke MK. 2004. Peroxisome proliferators-activated receptor a agonists as therapy for autoimmune disease. J Immunol 172:5790-5798.
27. Ludowyk PA, Hughes W, Hugh A, Willenborg DO, Rockett KA, Parish CR. 1993. Astrocytic hypertrophy: an important pathological feature of chronic experimental autoimmune encephalomyelitis in aged rats. J Neuroimmunol 48:121-134.
28. Mahad DJ, Ransohoff RM. 2003. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 15:23-32.
29. Martin R, McFarland HF. 1995. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 32:121-182.
30. Marx N, Kehrle B, Kohlhammer BK, Grub M, Koenig W, Hombach V, Libby P, Plutzky J. 2002. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90:703-710.
31. Mason JL, Suzuki K, Chaplin DD, Matsushima GK. 2001. Interleukin-1beta promotes repair of the CNS. J Neurosci 21:7046-7052.
32. McCarthy KD, deVellis J. 1980. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85:890-902.
33. McGeer PL, McGeer EG. 1999. Inflammation of the brain in Alzheimer's disease: implications for therapy. J Leukoc Biol 65:409-415.
34. Molkhtarian F, McFarlin DE, Raine C. 1984. Adoptive transfer of myelin basic protein-sensitized T cells produce chronic relapsing demyelinating disease in mice. Nature 309:356-358.
35. Natarajan C, Bright JJ. 2002. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling, and Th1 differentiation. Genes Immunol 3:59-70.
36. Niino M, Iwabuchi K, Kikuchi S, Ato M, Morohashi T, Ogata A, Tashiro K, Onoé K. 2001. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-γ. J Neuroimmunol 116:40-48.
37. Racke MK, Burnett D, Pak SK, Albert PS, Cannella B, Raine CS, McFarlin DE, Scott DE. 1995. Retinoid treatment of experimental allergic encephalomyelitis: IL-4 production correlates with improved disease course. J Immunol 154:450-458.
38. Raine CS. 1997. The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J Neuroimmunol 77:135-152.
39. Raine CS, Barnett LB, Brown A, McFarlin DE. 1980. Neuropathology of experimental allergic encephalomyelitis. Lab Invest 43:150-157.
40. Ricote M, Li AC, Wilson TM, Kelly CJ, Glass CK. 1998. The peroxisome proliferator activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79-82.
41. Ricote M, Huang JT, Welch JS, Glass CK. 1999. The peroxisome proliferator-activated receptor-γ (PPARγ) as a regulator of monocyte/macrophage function. J Leukoc Biol 66:733-739.
42. Sahrbacher UC, Lechner F, Eugster HP, Frei K, Lassmann H, Fontana A. 1998. Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible to experimental autoimmune encephalomyelitis. Eur J Immunol 28:1332-1338.
43. Samoilova EB, Horton JL, Hilliard B, Liu TS, Chen Y. 1998. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol 161:6480-6486.
44. Sean Riminton D, Korner H, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD. 1998. Challenging cytokine redundancy: inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necrosis factor-deficient, mice. J Exp Med 187:1517-1528.
45. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. 1998. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 84:238-249.
46. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Stricter RM, Frederiksen JL, Ransohoff RM. 1999. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 103:807-815.
47. Sriram S, Rodriguez M. 1997. Indictment of microglia as the villain in multiple sclerosis. Neurology 48:464-470.
48. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD. 1999. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104:383-389.
49. Swanborg RH. 1995. Animal models of human disease: experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin Immunol Immunopathol 77:4-13.
50. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. 1998. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285.
51. Wang J, Asensio VC, Campbell IL. 2002. Cytokines and chemokines as mediators of protection and injury in the central nervous system assessed in transgenic mice. Curr Top Microbiol Immunol 265:23-48.
52. Xiao BG, Link H. 1999. Antigen-specific T cells in autoimmune diseases with a focus on multiple sclerosis and experimental allergic encephalomyelitis. Cell Mol Life Sci 56:5-21.